However, the analysis of the metastatic melanoma dataset showed that the patients with the disease at stage III and with lower expression of the ACCN2 gene demonstrated better survival prognosis than the patients with the same stage of metastatic melanoma and with the elevated ACCN2 expression (Figure 11c). The gene discussed is ASIC1; the disease is metastatic melanoma.